医学临床研究
  2025年4月4日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (1): 45-48    DOI: 10.3969/j.issn.1671-7171.2023.01.014
  论著 本期目录 | 过刊浏览 | 高级检索 |
组织内DC-SIGN、TACC3及BMP4与原发性肝癌患者预后的相关性
后志刚1, 刘振辉2*
1.陕西省第四人民医院普外科,陕西 西安 710061;
2.神木市医院肝胆外科,陕西 榆林 719300
Correlation of Prognosis in Patients with Primary Liver Cancer to DC-SIGN,TACC3 and BMP4 Expression in Tissues
HOU Zhi-gang, LIU Zhen-hui
Department of General Surgery,The Fourth People's Hospital of Shaanxi Province,Xi'an Shaanxi 710061
全文: PDF (1210 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】 探讨影响原发性肝癌(PLC)患者预后的因素。【方法】 根据90例PLC患者三年预后情况分为死亡组(40例)和存活组(50例)。收集并比较两组患者的基础资料和实验室指标[树突状细胞特异性细胞间黏附分子-3结合非整合素(DC-SIGN)光密度值、骨形态发生蛋白4(BMP4)阳性率、转录相关酸性卷曲蛋白3(TACC3)水平];以受试者工作特征(ROC)曲线分析DC-SIGN光密度值、TACC3水平、BMP4阳性率预测PLC患者预后不良的价值;采用非条件Logistic逐步回归分析PLC患者预后不良的危险因素。【结果】 死亡组肿瘤分布双叶、有饮酒史、有淋巴结侵犯或远处转移、TNM分期Ⅲ~Ⅳ期的例数显著多于存活组(P<0.05),其DC-SIGN光密度值、TACC3水平、BMP4阳性率均显著高于存活组(P<0.05);ROC分析显示:患者DC-SIGN光密度值≥10.925×10-3/μm2、TACC3水平≥331.494 ng/g、BMP4阳性率≥79.883%是预测PLC患者预后不良的最佳截断值(均P<0.05);Logistic逐步回归分析显示:肿瘤分布双叶、有饮酒史、有淋巴结侵犯或远处转移、TNM分期Ⅲ~Ⅳ期、DC-SIGN光密度值≥10.925×10-3/μm2、TACC3水平≥331.494 ng/g、BMP4阳性率≥79.883%是PLC患者预后不良的危险因素(P<0.05)。【结论】 肿瘤分布、饮酒史、淋巴结侵犯或远处转移、TNM分期、DC-SIGN光密度值、TACC3水平、BMP4阳性率与PLC患者预后情况有密切相关。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
后志刚
刘振辉
关键词 肝肿瘤/病理学 骨形态发生蛋白质类 预后    
Abstract【Objective】 To investigate the prognostic factors of patients with primary liver cancer (PLC).【Methods】 A total of 90 PLC patients were divided into the death group (40 cases) and the survival group (50 cases) according to the three-year prognosis.The basic data and laboratory indicators of the two groups of patients [optical density value of dendritic cell specific intercellular adhesion molecule-3 binding non integrin (DC-SIGN),bone morphogenetic protein 4 (BMP4) level,and positive rate of transcription associated acid curl protein 3 (TACC3)] were collected and compared.DC-SIGN optical density value,TACC3 level and BMP4 positive rate were analyzed by ROC curve to predict the poor prognosis of PLC patients.Unconditional logistic stepwise regression analysis was used to identify the risk factors for poor prognosis of PLC patients.【Results】 The proportion of bilobular tumor distribution,alcohol drinking history,lymph node invasion or distant metastasis,TNM stage Ⅲ-Ⅳ in the death group were significantly higher than those in the survival group (P<0.05),whose DC-SIGN optical density,TACC3 level and BMP4 positive rate were significantly higher than those in the survival group (P<0.05).ROC analysis showed that DC-SIGN optical density ≥10.925×10-3/μm2,TACC3 level ≥331.494 ng/g,and BMP4 positive rate ≥79.883% were the cut-off values for predicting poor prognosis of PLC patients (all P<0.05),respectively.Logistic stepwise regression analysis showed that the bilobular tumor distribution,history of alcohol consumption,lymph node invasion or distant metastasis,TNM stage Ⅲ-Ⅳ,DC-SIGN optical density ≥10.925×10-3/μm2,TACC3 level ≥331.494 ng/g and positive rate of BMP4 ≥79.883% were risk factors for poor prognosis in PLC patients (P<0.05).【Conclusion】 Tumor distribution,drinking history,lymph node invasion,distant metastasis,TNM stage,DC-SIGN optical density value,TACC3 level,BMP4 positive rate were closely related to the prognosis of PLC patients.
Key wordsLiver Neoplasms/PA    Bone Morphogenetic Proteins    Prognosis
收稿日期: 2022-03-09     
中图分类号:  R735.7  
通讯作者: *, E-mail:463976143@qq.com   
引用本文:   
后志刚, 刘振辉. 组织内DC-SIGN、TACC3及BMP4与原发性肝癌患者预后的相关性[J]. 医学临床研究, 2023, 40(1): 45-48.
HOU Zhi-gang, LIU Zhen-hui. Correlation of Prognosis in Patients with Primary Liver Cancer to DC-SIGN,TACC3 and BMP4 Expression in Tissues. JOURNAL OF CLINICAL RESEARCH, 2023, 40(1): 45-48.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.01.014     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I1/45
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn